RELATION BETWEEN CLINICAL REMISSION AND TROUGH INFLIXIMAB LEVELS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
PKP-031
CLINICAL PHARMACOKINETICS OF EVEROLIMUS IN LUNG TRANSPLANTATION: STRATEGIES OF MONITORING
PKP-034
DETERMINATION OF METHOTREXATE IN CSF BY CHEMILUMINESCENCE USING THE ARCHITECT
PKP-015
ANALYSIS OF THE PREDICTIVE ABILITY OF DIFFERENT METHODS IN DOSAGE ADJUSTMENT OF DIGOXIN
PKP-036
LINEZOLID DOSE OPTIMISATION USING MONTE CARLO SIMULATION
PKP-035
FACTORS CORRELATED TO HIGH DOSE METHOTREXATE SEVERE INTOXICATION: NAUSEA AND VOMITING
PKP-033
ANALYSIS OF A DESIGN TO DETECT TRIPLE WHAMMY IN PATIENTS WITH DIGOXIN THERAPY
PKP-030
APPROPRIATENESS OF AN INITIAL PREFIXED DOSE OF VANCOMYCIN AND RISK FACTORS FOR OVERDOSE
PKP-029
PHARMACOGENETIC STUDY OF THE INFLUENCE OF POLYMORPHISMS IN THE TNFR1A AND FAS GENES ON THE RESPONSE TO RITUXIMAB AND CHEMOTHERAPY IN FOLLICULAR LYMPHOMA PATIENTS
PKP-027
SIGNIFICANT INTERACTIONS IN TREATMENT OF DRAVET SYNDROME
PKP-025
EFFECT OF ANTIANGIOGENIC TREATMENTS ON BIOMARKERS OF OXIDATIVE STRESS IN PATIENTS WITH AGE RELATED MACULAR DEGENERATION
PKP-024
THE FCGR2A (A >G) (RS1801274) GENETIC VARIANT AND THE EFFICACY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS
PKP-023
INTERLEUKIN 6 G >G GENETIC POLYMORPHISM (RS1800795) AND THE RESPONSE TO TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS
PKP-022
THE KCNMB1 (A >G) (RS703505) GENETIC VARIANT AND THE EFFICACY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS
PKP-021
RESULTS OF THE USE OF PHARMACOGENETICS IN THE CHOICE OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION WITH STENT
